Aarti Pharmalabs Limited has submitted its Q4 FY26 Results Presentation, detailing the company’s financial performance and strategic updates. The presentation covers key highlights, business overviews, manufacturing capabilities, R&D initiatives, and financial statements for both standalone and consolidated entities. It also provides insights into CAPEX plans and future outlook, emphasizing growth targets and strategic expansions.
Aarti Pharmalabs Limited: Q4 FY26 Results Presentation
Company Overview & Snapshot
Aarti Pharmalabs Limited (APL) is part of the diversified Aarti group, with a group turnover exceeding INR 150+ billion. The company is a globally recognized manufacturer of generic API, Xanthine derivatives, and a leading player in CDMO/CMO services. With over 25+ years of pharmaceutical excellence, APL boasts 220+ products, 63 patents filed, 7 manufacturing units, and 3 USFDA units. It holds a 15-20% global market share in Xanthine and maintains a strong credit rating of AA-.
Key Milestones & Geographical Presence
The company has achieved significant milestones since its inception in 1984, including commissioning of API manufacturing units, successful USFDA audits, and expansion of production capacities. Aarti Pharmalabs has a robust geographical presence with manufacturing units in Dombivli, Vapi, Tarapur, and Atali, catering to both domestic and international markets.
Manufacturing Capabilities & R&D
APL offers end-to-end capabilities under one umbrella, including hydrogenation facilities, cryogenic reactors, continuous manufacturing, HPAPI production, and specialized cyanation blocks. The company invests significantly in Research & Development, with 3 state-of-the-art R&D Centers, 122 R&D Process Scientists, and 63 process patents filed. They have developed and manufactured over 40+ products on kilo-lab scale in FY25 and commercialized 61 APIs.
Business Segments: Xanthine Derivatives & API/Intermediates
Aarti Pharmalabs is the largest Indian manufacturer of Xanthine Derivatives, with a current global market share of 15-20% targeted to reach 20-25% post capacity expansion to 9,000+ MTPA. In the API & Intermediates segment, APL specializes in HPAPIs for oncology, corticosteroids, and cytotoxic medicines, with 61 APIs commercialized and 11 new APIs under development.
CDMO & CMO Services
As a leading small molecule CDMO/CMO player, APL offers end-to-end services from process development to commercial manufacturing. The company works with 21 customers on 54 active projects, with significant growth projected in CDMO sales, estimated at 40-50% growth. Key services include process development, validation, and CMC documentation.
Financial Performance & Highlights (Q4 FY26)
For Q4 FY26, Aarti Pharmalabs reported operational revenue of INR 5,797 million and EBITDA of INR 1,341 million, with an EBITDA margin of 23.13%. The company reported a PAT of INR 620 million. For the full year FY26, operational revenue stood at INR 17,976 million, with EBITDA at INR 4,061 million and PAT at INR 1,762 million.
Capital Expenditure (CAPEX) Update
The company is undertaking significant CAPEX. The Greenfield Capex at the Atali Project (Gujarat) involves an estimated investment of INR 400 crores for a capacity of ~450 KL (Phase 1), focusing on Intermediates and CDMO/CMO. The Brownfield Capex at Tarapur (Maharashtra) is INR 210 crores to increase proposed capacity to 9,000 MTPA for Xanthine Derivatives.
Future Outlook
Aarti Pharmalabs is targeting a 15-18% Revenue & EBITDA CAGR over the next 3-4 years. The company is initiating R&D investment in FY27 towards TIDES (Peptides & Oligonucleotides) and evaluating a dedicated block for a specific CDMO project at Atali, with groundbreaking planned in FY27.
Capital Market Information
As of March 31, 2026, the Market Price was INR 589.25, with a Market Cap of INR 53,420.08 million and 90.66 million Equity Shares Outstanding. The shareholding pattern shows Promoters holding 43.08%, Public 41.12%, FII 8.39%, and DII 7.41%.
Disclaimer
This presentation contains forward-looking statements and is subject to risks and uncertainties. Investors are cautioned not to place undue reliance on these statements.
Source: BSE
